Indication-Based Pricing Sparks Interest In UK
Experts Advocate Flexible Drug Pricing Models For NHS
Executive Summary
Different prices for different medical conditions treated by the same drug and tying drug prices to the benefits they deliver are some of the recommendations made by a cross-sector expert panel to improve patient access to innovative cancer medicines.
You may also be interested in...
NICE Reform Plans Aim To Help Make Post-Brexit UK A ‘First-Launch’ Country
Following a Brexit-induced delay over the summer, England's HTA body NICE has come up with a concrete set of proposals that it says will help it “robustly and efficiently” evaluate innovative technologies such as advanced therapies, histology-independent cancer treatments, and technologies for rare diseases. Industry bodies have welcomed the plans, which have just been put out for consultation.
Better Data Tracking Could Hold Key To Indication-Based Pricing Progress
Indication-based pricing could become a reality with better infrastructure to track utilization data.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.